Results 201 to 210 of about 598,715 (406)

Long‐term human papillomavirus genotype‐specific risk of cervical high‐grade intraepithelial lesion and cancer—By age group and triage cytology

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Human papillomavirus (HPV) testing has revolutionized cervical cancer screening. Nonetheless, its optimal use for distinguishing between high‐ and low‐risk infections to leverage screening benefits remains to be established. Here, long‐term HPV genotype‐specific risk of precancerous cervical intraepithelial neoplasia grade 2 or higher was ...
Maija Vahteristo   +6 more
wiley   +1 more source

Trends in cervical cancer incidence in the Netherlands: A join‐point and age–period–cohort analysis (1989–2023)

open access: yesInternational Journal of Cancer, EarlyView.
What's New? This ecological study of trends in cervical cancer incidence from 1989 to 2023 in the Netherlands indicates a positive impact of screening, with a steady decline over the years. However, incidence increased from 2003 to 2023, particularly among younger cohorts, aligning with reduced participation and the introduction of more sensitive, high‐
Kelly Melisa Castañeda   +5 more
wiley   +1 more source

Programmed death ligand 1 testing in non–small cell lung carcinoma cytology cell block and aspirate smear preparations

open access: yesCancer Cytopathology, 2018
Bryce W. Noll   +7 more
semanticscholar   +1 more source

Increased incidence, survival, and registration quality of primary hepato‐pancreato‐biliary cancers in the Netherlands Cancer Registry

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Primary hepato‐pancreato‐biliary cancers have poor prognosis and their reporting often scores low on standard data quality indicators in population‐based cancer registries. This comprehensive evaluation of cases in the Netherlands Cancer Registry shows that both the incidence and survival rates of most primary hepato‐pancreato‐biliary ...
Lydia G. van der Geest   +13 more
wiley   +1 more source

Prospective multicenter validation of a next-generation sequencing panel using cytology specimens for lung cancer: cPANEL. [PDF]

open access: yesBMC Cancer
Morikawa K   +15 more
europepmc   +1 more source

Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Bladder cancer exhibits a highly heterogeneous molecular landscape and treatment response. The dysregulation of RNA modifications such as m6A has been involved in cancer initiation and progression. This study comprehensively analyzed the expression of the main catalytic component of the m6A methylation machinery in bladder tumors across one
Katerina‐Marina Pilala   +10 more
wiley   +1 more source

First‐Line Osimertinib in Patients with EGFR‐Mutant Advanced Non‐Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

open access: yesThe Oncologist, EarlyView., 2021
Abstract Lessons Learned Osimertinib has confirmed effectiveness in this real‐world population of patients with EGFR‐mutant advanced non‐small cell lung cancer. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain
Martina Lorenzi   +21 more
wiley   +1 more source

Home - About - Disclaimer - Privacy